TASUC-Neo
Phase 1 Terminated
2 enrolled
EV-103
Phase 1/2 Terminated
348 enrolled 2 FDA
GETUGV04
Phase NA Terminated
69 enrolled 9 charts
PRESERVE3
Phase 2 Terminated
92 enrolled 24 charts
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Phase 2 Terminated
4 enrolled 9 charts
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Phase 2 Terminated
7 enrolled 9 charts
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Phase 1/2 Terminated
12 enrolled
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Phase 1/2 Terminated
92 enrolled 15 charts
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Phase 2 Terminated
32 enrolled 6 charts
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
Phase 2 Terminated
3 enrolled 9 charts
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
Phase 2 Terminated
21 enrolled 4 charts
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
Phase 2 Terminated
8 enrolled
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
Phase 3 Terminated
521 enrolled 18 charts
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
Phase 3 Terminated
1 enrolled
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
Phase 2 Terminated
9 enrolled 7 charts
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 Terminated
2 enrolled 5 charts
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Phase 2 Terminated
41 enrolled
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Phase 1 Terminated
14 enrolled
Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin
Phase 2 Terminated
100 enrolled
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
Phase 1 Terminated
44 enrolled
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
Phase 3 Terminated
100 enrolled
Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
Phase 2 Terminated
73 enrolled
Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer
Phase 2 Terminated
43 enrolled